Replies to post #17687 on ProText Mobility Inc (TXTM)

[Natural Trader]

good news Medical Marijuana approved in South Africa november 24 ,2016
The Department has indicated that the new regulatory framework could be available as early as the end of January 2017 for stakeholder comment, and could be implemented as soon as April 2017
https://btl.co.za/government-just-approved-medical-marijuana-in-south-africa/

[mymonies]

very good, it is like PLPL wanted an expression in the MJ in South Africa without having their name up front, they wanted a different name than their own to make things cleaner
very nice set up here
and not just the MJ but other retail as well
that way they have their science research and they have their outlet
separate the Two for better control and movement
very cool stuff TXTM
multipennies coming here soon

[DD_dempsey]

Stervc with this HUGE validation of TXTM/PLPL Marijuana connection

It is my opinion, that Artist and you have enlightened me to something far greater than I initially thought.

PLPL current CEO Roger Baylis-Duffield, Chairman and Chief Executive Officer, will be taking over TXTM under the new corporate identity and ticker change coming as per the 8k.

JUST HOW BIG A DEAL IS THIS stock ?

How many other companies do we know of, represent the MMJ growing Industry in the nation of South Africa?

FACTS:
In April 2014, Plandaí applied for a research license under the South African Medicines and Related Substances Act No. 101 of 1965 to undertake defined cannabis-related medicinal research; however, the South African Government took no action on this request and the Company halted its development efforts.

HOWEVER.....Due to the Department of Health's revised position and support of the Ambrosini bill, Plandaí's South Africa legal representatives sent a letter on December 5, 2016 to the South African Director-General of Health, requesting clarification on the Department of Health's position on granting research licenses in light of the Dept. of Health's endorsement. Should the Dept. of Health decide to grant research licenses, Plandaí may then move forward with plans to validate and clinically develop its Phytofare® extract in South Africa in conjunction with North West University's Drug Development Platform.

The Company's 2014 Cannabis initiative was focused on the possible development of a cannabis extract utilizing its Phytofare® technology with the objective to design a non-psychoactive, full profile Cannabis complex of all 113 known cannabinoids. The Company's unique extraction process should prohibit the metabolizing of non-psychoactive acid-form cannabinoids (THC-A and THCB), resulting in an extract that could deliver all the potential medical benefits from a full cannabinoid complex without being psychoactive.

Roger Baylis-Duffield, Chairman and Chief Executive Officer of Plandaí Biotechnology, stated, "We are pleased to see this change in the department's stance on medical cannabis and are looking forward to producing and testing our Phytofare® cannabinoid complex in the near future in South Africa. It gives us pleasure in knowing that Dr. Ambrosini's bill is close to being passed even after his death and we hope to continue in his memory with research for which he was so passionate."

About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable extracts. It controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare® extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include cosmeceutical, wellness, anti-aging, pharmaceutical and animal husbandry.

[Oceanfreedom]

Hi Stervc,

Agree. Know your DD well. Always appreciated. Been around long time, just not a big poster. I would just add this: investment that is being setup to help the entire world. So as not to pigeon hole it here. For example, Just because OWC* is operating in Israel does not limit them to home country. Same here, yes home country will benefit, but opportunity to create treatments used around the world here. They setup TXTM to essentially be the OWC* arm of the company. Researching and creating proprietary treatments using their technology.

[balamidas]

Sterling ,the DD from the 8-k on TXTM are huge ! i am expecting them to put a PR soon